Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

AMCP Nexus 2023

All Publications

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

AMCP Nexus 2023

Sekeres, et. al.

[facetwp facet="publication_load_more"]